Evofem Biosciences, Inc. (NASDAQ:EVFM) is reporting third quarter financial results on Monday 9th November 2020, after market close.
According to analysts surveyed by Thomson Reuters, EVFM is expected to report 3Q20 loss of $ 0.44 per share from revenue of $ 1.72 million.
For the full year, analysts anticipate top line of $ 8.35 million, while looking forward to loss of $ 1.99 per share bottom line.
Stock Performance
On Friday, shares of Evofem Biosciences, Inc. has traded high as $ 2.51 and has cracked $ 2.39 on the downward trend, reaching $ 2.45 with volume of 1.06 million shares.
According to the previous trading day, closing price of $ 2.45, representing a 29.84 % increase from the 52 week low of $ 1.91 and a 66.93 % decrease over the 52 week high of $ 7.50.
The company has a market capital of $ 199.14 million and is part of the Healthcare sector and Biotechnology industry.
Recent Analyst recommendations
- On 2nd October 2020, initiated by Stifel Nicolaus at Buy rating, with $ 5.00 target price.
Evofem Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes womens sexual and reproductive health products. Its lead product candidate is Amphora, a non-hormonal woman-controlled vaginal gel, which is in Phase 3 clinical trial for the prevention of pregnancy; and in Phase 2b trial for the prevention of chlamydia and gonorrhea in women. The company is also developing multi-purpose vaginal pH regulator gel product candidate for the reduction of recurrent bacterial vaginosis.
